Osteocalcin Antibody (2H9F11F8) Summary
| Immunogen |
Recombinant human osteocalcin protein
|
| Specificity |
This product recognizes intact human and bovine osteocalcin in a “2 site” assay and reacts with osteocalcin fragments corresponding to amino acids 15-31 and 20-43 of the native molecule. It does not recognize fragments representing amino acids 1-19 or 7-19.
|
| Isotype |
IgG2a
|
| Clonality |
Monoclonal
|
| Host |
Mouse
|
| Gene |
BGLAP
|
| Purity |
Protein A purified
|
| Innovators Reward |
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
|
Applications/Dilutions
| Dilutions |
|
Packaging, Storage & Formulations
| Storage |
Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
|
| Buffer |
Phosphate buffered saline
|
| Preservative |
0.09% Sodium Azide
|
| Concentration |
1.0 mg/ml
|
| Purity |
Protein A purified
|
Alternate Names for Osteocalcin Antibody (2H9F11F8)
- BGLAP
- BGP
- bone gamma-carboxyglutamate (gla) protein (osteocalcin)
- bone gamma-carboxyglutamate (gla) protein
- Bone Gla protein
- Gamma-carboxyglutamic acid-containing protein
- OC
- OCN
- Osteocalcin
Background
Osteocalcin belongs to the osteocalcin/matrix Gla protein family and constitutes 1 to 2% of the total bone protein. It is a 49 amino acid single chain vitamin K dependent protein, made by osteoblasts, and is a major component of the noncollagenous bone matrix. Post translational modification by a vitamin K dependent carboxylase produces three gamma carboxyglutamic acid residues at positions 17, 21 and 24, giving it a high affinity for calcium. It also binds strongly to apatite.
Sixty to ninety percent of de novo synthesized osteocalcin is incorporated into the bone matrix where it binds to hydroxyapatite during matrix mineralization. The remainder of the osteocalcin is released into the circulation where it can be measured as a sensitive marker of bone formation. Osteocalcin found in serum is almost exclusively derived from the bone formation with little or no contribution from the resorption process. Drugs acting primarily on bone resorption, such as bisphosphonates, induce a rapid decline in specific bone resorption markers, whereas osteocalcin levels only change after extended therapy periods, in accordance with the expected dynamics of a bone formation marker.
Serum osteocalcin is elevated in diseases characterized by increased bone turnover such as osteoporosis, hyperparathyroidism and Pagets disease, and low in conditions associated with low bone turnover such as hypoparathyroidism and growth hormone deficiency.
Sixty to ninety percent of de novo synthesized osteocalcin is incorporated into the bone matrix where it binds to hydroxyapatite during matrix mineralization. The remainder of the osteocalcin is released into the circulation where it can be measured as a sensitive marker of bone formation. Osteocalcin found in serum is almost exclusively derived from the bone formation with little or no contribution from the resorption process. Drugs acting primarily on bone resorption, such as bisphosphonates, induce a rapid decline in specific bone resorption markers, whereas osteocalcin levels only change after extended therapy periods, in accordance with the expected dynamics of a bone formation marker.
Serum osteocalcin is elevated in diseases characterized by increased bone turnover such as osteoporosis, hyperparathyroidism and Pagets disease, and low in conditions associated with low bone turnover such as hypoparathyroidism and growth hormone deficiency.
